Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ivan S F Chan

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
Human Vaccines|October 29, 2010
Concomitant administration of zoster and pneumococcal vaccines in adults ≥60 years oldC Raina MacIntyre, Tony Egerton, Malcolm McCaughey, et al.
Journal of the American Geriatrics Society|September 25, 2010
Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adultsKenneth E Schmader, Gary R Johnson, Patricia Saddier, et al.
Journal of Medical Virology|March 11, 2003
Measurement of cell-mediated immunity with a Varicella-Zoster Virus-specific interferon-gamma ELISPOT assay: responses in an elderly population receiving a booster immunizationJeffrey G Smith, Myron Levin, Rupert Vessey, et al.
The Lancet. Infectious Diseases|August 11, 2019
Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trialKathleen M Mullane, Vicki A Morrison, Luis H Camacho, et al.
Clinical and Vaccine Immunology : CVI|December 14, 2007
A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of ZostavaxLarry I Gilderman, James F Lawless, Thomas M Nolen, et al.
The Journal of Infectious Diseases|August 3, 2013
Varicella-zoster virus-specific antibody responses in 50-59-year-old recipients of zoster vaccineMyron J Levin, Kenneth E Schmader, John W Gnann, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 1, 2012
Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 yearsKenneth E Schmader, Myron J Levin, John W Gnann, et al.
Journal of the American Geriatrics Society|October 3, 2007
Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and olderBoris Kerzner, Alexander V Murray, Eric Cheng, et al.
Brain, Behavior, and Immunity|February 19, 2011
Major depressive disorder and immunity to varicella-zoster virus in the elderlyMichael R Irwin, Myron J Levin, Carmen Carrillo, et al.
The Journal of Infectious Diseases|November 1, 2003
Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccineMyron J Levin, Jeffrey G Smith, Robin M Kaufhold, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
Human Vaccines|October 29, 2010
Concomitant administration of zoster and pneumococcal vaccines in adults ≥60 years oldC Raina MacIntyre, Tony Egerton, Malcolm McCaughey, et al.
Journal of the American Geriatrics Society|September 25, 2010
Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adultsKenneth E Schmader, Gary R Johnson, Patricia Saddier, et al.
Journal of Medical Virology|March 11, 2003
Measurement of cell-mediated immunity with a Varicella-Zoster Virus-specific interferon-gamma ELISPOT assay: responses in an elderly population receiving a booster immunizationJeffrey G Smith, Myron Levin, Rupert Vessey, et al.
The Lancet. Infectious Diseases|August 11, 2019
Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trialKathleen M Mullane, Vicki A Morrison, Luis H Camacho, et al.
Clinical and Vaccine Immunology : CVI|December 14, 2007
A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of ZostavaxLarry I Gilderman, James F Lawless, Thomas M Nolen, et al.
The Journal of Infectious Diseases|August 3, 2013
Varicella-zoster virus-specific antibody responses in 50-59-year-old recipients of zoster vaccineMyron J Levin, Kenneth E Schmader, John W Gnann, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 1, 2012
Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 yearsKenneth E Schmader, Myron J Levin, John W Gnann, et al.
Journal of the American Geriatrics Society|October 3, 2007
Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and olderBoris Kerzner, Alexander V Murray, Eric Cheng, et al.
Brain, Behavior, and Immunity|February 19, 2011
Major depressive disorder and immunity to varicella-zoster virus in the elderlyMichael R Irwin, Myron J Levin, Carmen Carrillo, et al.
The Journal of Infectious Diseases|November 1, 2003
Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccineMyron J Levin, Jeffrey G Smith, Robin M Kaufhold, et al.
Pageof 5